Compare Amphastar Pharmaceuticals Inc (AMPH) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Consumer Staples Select Sector SPDR Fund trades at $84.28. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLP | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $90.00 |
52-Week Low | $16.87 | $75.61 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XLP trades at $84.12, up 1.11% with a bearish technical signal despite neutral oscillators. The ETF maintains strong analyst support with 100% buy ratings and offers defensive exposure to consumer staples. Recent news highlights XLP's role as a safe haven during market uncertainty, with a 2.6% dividend yield providing income stability amid economic pressures.
The fund's defensive positioning and high dividend yield present opportunity during market volatility, though concentration in 36 holdings increases single-stock risk. Technical weakness suggests near-term pressure, but long-term fundamentals remain sound for investors seeking stable consumer staples exposure with income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
